Tobacco and nicotine population health planning for Aboriginal and Torres Strait Islander population growth
Related Experiment Video
Updated: Jan 16, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Rohan M Telford1, Raymond Lovett1, Christina Heris1
1Yardhura Walani, National Centre for Epidemiology and Population Health, Australian National University (ANU), Canberra, ACT, Australia.
Abstract:
Aboriginal and Torres Strait Islander population growth has important implications for tobacco and nicotine health planning. Using the Australian Bureau of Statistics (ABS) DataLab, we examined weighted estimates of the absolute number of Aboriginal and Torres Strait Islander peoples aged 18 years and over, drawing on the 2012-13 and 2018-19 National Aboriginal and Torres Strait Islander Health Surveys. We compared the absolute number of people who currently smoke, stratified by age, state/territory, and sex. There was a 2.5 percentage point decline in smoking prevalence over this period, but the estimated number of Aboriginal and Torres Strait Islander adults who smoke increased by ∼43 000, reaching 211 000 (95% confidence interval: 199 746-221 616) in 2018. This growth is largely attributable to population increases driven by higher birth rates. Absolute increases in both the number of people who smoked and those who did not smoke varied by age group, jurisdiction, and geography, with the largest increases observed among those aged 55-64 years and in areas experiencing the most rapid population growth. These findings highlight the need for programs, policies, and health services-including tobacco and nicotine resistance measures-to be adequately resourced and responsive to changing Aboriginal and Torres Strait Islander population dynamics. While progress is being made in reducing smoking prevalence, the expanding population means that the total number of people impacted by commerical tobacco remains high. This highlights the need for sustained future-focused planning and investment to eradicate tobacco-related death and disease.
More Related Videos
09:30A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
Published on: January 18, 2018
06:39Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
Published on: August 28, 2017
Related Concept Videos
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Population Growth
Conservation of Declining Populations
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Analysis of Population Pharmacokinetic Data
Stress Prevention and Stress Management Techniques IV